Skip to main content
SpringerLink
Log in

Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis?

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Neer RM et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441

    Article  CAS  Google Scholar 

  2. Compston J (2005) Recombinant parathyroid hormone in the management of osteoporosis. Calcif Tissue Int 77: 65–71

    Article  CAS  Google Scholar 

  3. Black DM et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207–1215

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. University of Cambridge, School of Clinical Medicine, Department of Medicine, Box 157, Addenbrooke's Hospital, Cambridge, Cambridgeshire CB2 2QQ, UK jec1001@cam.ac.uk

Authors and Affiliations

  1. J Compston is a Professor at the University of Cambridge School of Clinical Medicine, Cambridge, UK.,

    Juliet Compston

Authors
  1. Juliet Compston
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Paid advisory roles for the following:

Crescent diagnostics (Advisory Board)

Novartis (DSMB)

Amgen (DMC)

Servier (Advisory Boards, speaking engagements)

Procter & Gamble and Sanofi Aventis (Advisory Boards, speaking engagements)

Shire Pharmaceuticals (Advisory Board)

Nycomed (Advisory Board. speaking engagements)

Eli Lilly (speaking engagements)

Research grants from the following:

Procter & Gamble: RCT of risedronate in adults with cystic fibrosis

Servier: Study of bone histomorphometry in postmenopausal women receiving alendronate or strontium ranelate

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J. Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis?. Nat Rev Rheumatol 3, 324–325 (2007). https://doi.org/10.1038/ncprheum0501

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0501

  • Springer Nature Limited

Search

Navigation